Background: Leishmania (Viannia) shawi parasite was first characterized in 1989. Recently the protective effects of soluble leishmanial antigen (SLA) from L. (V.) shawi promastigotes were demonstrated using BALB/c mice, the susceptibility model for this parasite. In order to identify protective fractions, SLA was fractionated by reverse phase HPLC and five antigenic fractions were obtained. Methods: F1 fraction was purified from L. (V.) shawi parasite extract by reverse phase HPLC. BALB/c mice were immunized once a week for two consecutive weeks by subcutaneous routes in the rump, using 25 mu g of F1. After 1 and 16 weeks of last immunization, groups were challenged in the footpad with L. (V.) shawi promastigotes. After 2 months, those same...
This study evaluated two vaccine candidates for their effectiveness in protecting BALB/c mice agains...
Background and Significance. The only immunizing intervention shown to be effective for preventing h...
Background and Significance. The leishmaniases are a diverse group of diseases with four major clini...
Background: Leishmania (Viannia) shawi parasite was first characterized in 1989. Recently the protec...
Abstract\ud \ud Background\ud \ud Le...
Abstract Background Leishmania (Vi...
Background: Leishmania (Viannia) shawi parasite was first characterized in 1989. Recently the protec...
Abstract\ud \ud Background\ud \ud Le...
Abstract Background Leishmania (Vi...
Abstract Background Leishmania (Viannia) shawi parasite was first characterized in 1989. Recently th...
Leishmania (Viannia) shawi causes cutaneous lesions in humans. Parasite antigens conferring signific...
Leishmania (Viannia) shawi was characterized only recently, and few studies concerning the immunogen...
Leishmania (Viannia) shawi was characterized only recently, and few studies concerning the immunogen...
Experimental vaccines have been developed to protect against leishmaniasis using the BALB/c mice mod...
Visceral leishmaniasis (VL), caused by the intracellular parasite Leishmania donovani is a major pub...
This study evaluated two vaccine candidates for their effectiveness in protecting BALB/c mice agains...
Background and Significance. The only immunizing intervention shown to be effective for preventing h...
Background and Significance. The leishmaniases are a diverse group of diseases with four major clini...
Background: Leishmania (Viannia) shawi parasite was first characterized in 1989. Recently the protec...
Abstract\ud \ud Background\ud \ud Le...
Abstract Background Leishmania (Vi...
Background: Leishmania (Viannia) shawi parasite was first characterized in 1989. Recently the protec...
Abstract\ud \ud Background\ud \ud Le...
Abstract Background Leishmania (Vi...
Abstract Background Leishmania (Viannia) shawi parasite was first characterized in 1989. Recently th...
Leishmania (Viannia) shawi causes cutaneous lesions in humans. Parasite antigens conferring signific...
Leishmania (Viannia) shawi was characterized only recently, and few studies concerning the immunogen...
Leishmania (Viannia) shawi was characterized only recently, and few studies concerning the immunogen...
Experimental vaccines have been developed to protect against leishmaniasis using the BALB/c mice mod...
Visceral leishmaniasis (VL), caused by the intracellular parasite Leishmania donovani is a major pub...
This study evaluated two vaccine candidates for their effectiveness in protecting BALB/c mice agains...
Background and Significance. The only immunizing intervention shown to be effective for preventing h...
Background and Significance. The leishmaniases are a diverse group of diseases with four major clini...